Amyloid-β-Induced Dendritic Spine Elimination Requires Ca2+-Permeable AMPA Receptors, AKAP-Calcineurin-NFAT

Tyler P Martinez1,2,3, Matthew E Larsen2,4, Emily Sullivan2

  • 1Pharmacology PhD Program, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045.

Eneuro
|February 8, 2024
PubMed

Insights

Alzheimer's disease (AD) involves amyloid-beta (Aβ) causing synapse loss. This study reveals a pathway where Aβ triggers Mdm2, an E3-ubiquitin ligase, leading to dendritic spine loss in the hippocampus.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Biology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) accumulation and synaptic dysfunction.
  • Soluble Aβ oligomers impair learning, memory, and synaptic plasticity in the hippocampus.
  • Calcineurin (CaN) signaling is broadly implicated in Aβ-induced synaptotoxicity, but synapse-specific mechanisms remain unclear.

Purpose of the Study:

  • To elucidate the specific postsynaptic signaling pathway by which Aβ induces dendritic spine loss in hippocampal neurons.
  • To identify key molecular players involved in Aβ-mediated synaptotoxicity at the synapse.

Main Methods:

  • Pharmacologic and genetic approaches in rat and mouse hippocampal neurons.
  • Investigation of signaling pathways involving A kinase-anchoring protein 150 (AKAP150), calcineurin (CaN), and nuclear factor of activated T-cells (NFAT).
  • Analysis of the role of Ca2+-permeable AMPA receptors (CP-AMPARs) and the E3-ubiquitin ligase Mdm2 in Aβ-induced spine loss.

Main Results:

  • Aβ-induced dendritic spine loss requires postsynaptic AKAP150-scaffolded CaN signaling.
  • Ca2+-permeable AMPA receptors (CP-AMPARs) are essential upstream mediators of this AKAP-CaN pathway.
  • CaN-dependent NFAT transcription factors are required downstream, leading to the upregulation of the E3-ubiquitin ligase Mdm2.
  • Mdm2 enzymatic activity is necessary for Aβ-mediated dendritic spine loss.

Conclusions:

  • Aβ triggers a synapse-to-nucleus signaling cascade involving AKAP150, CaN, and NFAT.
  • This pathway culminates in the transcriptional upregulation of Mdm2, which mediates Aβ-induced spine loss.
  • Mdm2 represents a potential therapeutic target for mitigating synaptic damage in Alzheimer's disease.

Related Concept Videos